BioNTech SE (BVMF:B1NT34)
Brazil · Delayed Price · Currency is BRL 32.33
-1.92 (-5.61%)
At close: Apr 28, 2026
BioNTech SE Revenue
In the year 2025, BioNTech SE had annual revenue of 2.87B EUR with 4.32% growth. BioNTech SE had revenue of 907.40M in the quarter ending December 31, 2025, a decrease of -23.75%.
Revenue
2.87B EUR
Revenue Growth
+4.32%
P/S Ratio
6.92
Revenue / Employee
367.61K EUR
Employees
7,807
Market Cap
128.51B BRL
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.87B | 118.80M | 4.32% |
| Dec 31, 2024 | 2.75B | -1.07B | -27.96% |
| Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | 108.60M | -18.98M | -14.87% |
| Dec 31, 2018 | 127.58M | 65.98M | 107.11% |
| Dec 31, 2017 | 61.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rede D'Or São Luiz | 55.73B |
| Raia Drogasil | 44.25B |
| Empreendimentos Pague Menos | 14.91B |
| Diagnósticos da América | 11.17B |
| Fleury | 8.29B |
| Hypera | 7.70B |
| Oncoclínicas do Brasil Serviços Médicos | 5.74B |
| Dimed S.A. Distribuidora de Medicamentos | 5.51B |
BioNTech SE News
- 8 days ago - Two experimental drugs showed striking early results against pancreatic cancer - WSJ
- 9 days ago - BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026 - GlobeNewsWire
- 19 days ago - BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - GlobeNewsWire
- 4 weeks ago - Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles - Reuters
- 5 weeks ago - BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer - GlobeNewsWire
- 7 weeks ago - BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls - Benzinga
- 7 weeks ago - BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 7 weeks ago - One simple reason why BioNTech stock is a raging buy on today's crash - Invezz